BOGOTA, Colombia – Brazil's health surveillance agency, Anvisa, approved the commercialization of Sylvant (siltuximab) to treat patients with multicentric Castleman's disease (MCD) who do not have HIV and the human herpesvirus-8 infection. The application was filed by Sao Paulo-based Janssen-Cilag Farmacêutica, a subsidiary of Belgium's Janssen Pharmaceutical, which in turn is owned by Johnson & Johnson, of New Brunswick, N.J.

BOGOTA, Colombia – The biotech sector is benefiting from better relations between the U.S. and Cuba, a country that while poor has a history of drug research and development.

BOGOTA, Colombia – The Brazilian health surveillance agency Anvisa has issued a license for Remsima (infliximab), which gives the green light for Celltrion Inc. to distribute its biosimilar in the Latin American country under the bioequivalence provisions.

SAO PAULO, Brazil – A group of 11 Latin American countries has taken a significant step toward unifying their drug regulations by allowing for a single registration.